Conversion chemotherapy for unresectable or recurrent colorectal cancer.
Conversion therapy to surgical resection is associated with prolonged survival and even cure in patients with unresectable or borderline metastatic colorectal cancer(mCRC). The indication should be decided after close considerations to the patient's background and the mutation status of RAS/BRAF. The conversion strategy should be chosen especially for liver limited disease (LLD). Though the systemic chemotherapy with molecular targeted drug, such as bevacizumab, cetuximab and panitumumab lead to improved response and conversion rate, the best regimen for the conversion has not yet been elucidated. According to the result of KSCC0802 and KSCC1002, we are planning ATOM trial, which compare the progression free survival after 1" line treatment of modified FOLFOX6+either panitumumab or bevaci- zumab for patients with LLD.